CRO: Contract Research Organisation

Imagine a film studio that owns a brilliant script but has neither its own camera crew nor editing suite, so it hires a specialist production house to actually shoot and assemble the film on its behalf, start to finish, while the studio retains ownership of the finished work. A Contract Research Organisation plays almost exactly this role for the research side of drug development.

A CRO provides outsourced research services to pharmaceutical and biotech companies, most visibly running clinical trials, recruiting patients, managing trial sites, collecting and analysing data, and preparing the regulatory submissions built on that data, but also earlier-stage work like preclinical research and toxicology studies. Crucially, a CRO does not manufacture anything, it sits entirely on the research and evidence-generation side of a drug's journey, before manufacturing ever becomes relevant.

This exists because running a rigorous, multi-country Phase III clinical trial, already covered elsewhere on this site, requires specialised operational infrastructure, regulatory expertise across multiple jurisdictions, and trial site relationships that most individual drug developers, especially smaller biotech companies, would find prohibitively expensive and slow to build themselves for what might be a single drug candidate.

India has built a genuinely competitive CRO industry, drawing on a large patient population for trial recruitment, a strong base of medically trained researchers, and costs meaningfully below those in the US or Europe, making Indian CROs an increasingly common choice for global pharmaceutical companies running large, multi-country trials.

Whenever a drug's regulatory submission cites clinical data gathered across multiple Indian trial sites, a CRO was very likely the company that actually planned, ran and monitored that entire multi-site process, well before the resulting drug ever reaches a CDMO or CMO for actual manufacturing.